Citigroup Inc Revance Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 77,051 shares of RVNC stock, worth $198,021. This represents 0.0% of its overall portfolio holdings.

Number of Shares

77,051

Previous 24,919 209.21%

Holding current value

$198,021

Previous $64,000 209.38%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.57 - $2.57 $133,979 - $133,979	52,132 Added 209.21%	77,051 $198,000
Q2 2024 Aug 12, 2024	SELL	$2.34 - $4.73 $83,285 - $168,350	-35,592 Reduced 58.82%	24,919 $64,000
Q1 2024 May 10, 2024	SELL	$4.65 - $9.31 $143,113 - $286,533	-30,777 Reduced 33.71%	60,511 $297,000
Q4 2023 Feb 09, 2024	BUY	$5.81 - $11.2 $244,386 - $471,105	42,063 Added 85.45%	91,288 $802,000
Q3 2023 Nov 09, 2023	BUY	$11.47 - $25.07 $120,629 - $263,661	10,517 Added 27.17%	49,225 $564,000
Q2 2023 Aug 10, 2023	BUY	$24.7 - $37.61 $660,675 - $1.01 Million	26,748 Added 223.65%	38,708 $979,000
Q1 2023 May 11, 2023	SELL	$18.36 - $35.27 $530,750 - $1.02 Million	-28,908 Reduced 70.74%	11,960 $385,000
Q4 2022 Feb 09, 2023	SELL	$18.32 - $30.66 $556,726 - $931,726	-30,389 Reduced 42.65%	40,868 $754,000
Q3 2022 Nov 10, 2022	BUY	$14.33 - $28.47 $672,435 - $1.34 Million	46,925 Added 192.85%	71,257 $1.92 Million
Q2 2022 Aug 10, 2022	BUY	$11.52 - $20.4 $136,869 - $242,372	11,881 Added 95.42%	24,332 $336,000
Q1 2022 May 12, 2022	SELL	$12.36 - $20.31 $219,501 - $360,685	-17,759 Reduced 58.79%	12,451 $243,000
Q4 2021 Feb 10, 2022	BUY	$12.46 - $27.87 $23,636 - $52,869	1,897 Added 6.7%	30,210 $493,000
Q3 2021 Nov 10, 2021	BUY	$25.78 - $33.21 $729,909 - $940,274	28,313 New	28,313 $789,000

Others Institutions Holding RVNC

# of Institutions

232

Shares Held

82.1M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account